A Phase 1 interventional study of Metformin/Gliclazide Fixed Combination and Metformin in Healthy, sponsored by Merck KGaA, Darmstadt, Germany. Completed at 1 site in Germany. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2019-07-16.
Sponsored by Merck KGaA, Darmstadt, Germany · Phase 1, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This study investigated the bioequivalence and drug-drug interaction of Metformin/Gliclazide fixed combination tablet compared to co-administration of individual tablets of Metformin and Gliclazide.
Merck KGaA, Darmstadt, Germany is the lead sponsor of 275 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received single oral dose of metformin 1000 milligram (mg) and gliclazide 30 mg fixed combination tablet in treatment period 1 followed by concomitant oral dosing of metformin 1000 mg and gliclazide 30 mg in treatment period 2 followed by single oral dose of metformin 1000 mg in treatment period 3 and then a single oral dose of gliclazide 30 mg in treatment period 4. Each treatment period was separated by a 14-day wash-out period.
Drug: Metformin/Gliclazide Fixed Combination · Drug: Metformin · Drug: Gliclazide
Participants received concomitant oral dosing of metformin 1000 mg and gliclazide 30 mg in treatment period 1 followed by single oral dose of gliclazide 30 mg in treatment period 2 followed by single oral dose of metformin 1000 mg and gliclazide 30 mg fixed combination tablet in treatment period 3 and then single oral dose of metformin 1000 mg in treatment period 4. Each treatment period was separated by a 14-day wash-out period.
Drug: Metformin/Gliclazide Fixed Combination · Drug: Metformin · Drug: Gliclazide
Participants received single oral dose of metformin 1000 mg in treatment period 1 followed by single oral dose of metformin 1000 mg and gliclazide 30 mg fixed combination tablet in treatment period 2 followed by single oral dose of gliclazide 30 mg in treatment period 3 and then concomitant oral dosing of metformin 1000 mg and gliclazide 30 mg in treatment period 4. Each treatment period was separated by a 14-day wash-out period.
Drug: Metformin/Gliclazide Fixed Combination · Drug: Metformin · Drug: Gliclazide
Participants received single oral dose of gliclazide 30 mg in treatment period 1 followed by single oral dose of metformin 1000 mg in treatment period 2 followed by concomitant oral dosing of metformin 1000 mg and gliclazide 30 mg in treatment period 3 and then single oral dose of metformin 1000 mg and gliclazide 30 mg fixed combination tablet in treatment period 4. Each treatment period was separated by a 14-day wash-out period.
Drug: Metformin/Gliclazide Fixed Combination · Drug: Metformin · Drug: Gliclazide
Participants received single oral dose of Metformin and Gliclazide fixed combination tablet in treatment period 1, 2, 3 or 4.
Participants received single oral dose of Metformin tablet in treatment period 1, 2, 3 or 4.
Participants received single oral dose of Gliclazide tablet in treatment period 1, 2, 3 or 4.
Area Under the Plasma Concentration-Time Curve From Time Zero to Last Measurable Concentration (AUC0-t) of Metformin
Time frame: Pre-dose, 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 16, 24, 28, 32, 48, 72, 96, 120, 144 and 168 hours post-dose
Area Under the Plasma Concentration-Time Curve From Time Zero to Last Measurable Concentration (AUC0-t) of Gliclazide
Time frame: Pre-dose, 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 16, 24, 28, 32, 48, 72, 96, 120, 144 and 168 hours post-dose
Maximum Observed Plasma Concentration (Cmax) of Metformin
Time frame: Pre-dose, 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 16, 24, 28, 32, 48, 72, 96, 120, 144 and 168 hours post-dose
Maximum Observed Plasma Concentration (Cmax) of Gliclazide
Time frame: Pre-dose, 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 16, 24, 28, 32, 48, 72, 96, 120, 144 and 168 hours post-dose
Area Under the Plasma Concentration-time Curve From Time Zero to Infinity (AUC0-inf) of Metformin
AUC (0-inf) is defined as the area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time (0-inf).
Time frame: Pre-dose, 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 16, 24, 28, 32, 48, 72, 96, 120, 144 and 168 hours post-dose
Area Under the Plasma Concentration-time Curve From Time Zero to Infinity (AUC0-inf) of Gliclazide
AUC (0-inf) is defined as the area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time (0-inf).
Time frame: Pre-dose, 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 16, 24, 28, 32, 48, 72, 96, 120, 144 and 168 hours post-dose
Apparent Volume of Distribution (Vz/f) of Metformin
Vz/f was defined as apparent volume of distribution during terminal phase after non-intravenous administration.
Time frame: Pre-dose, 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 16, 24, 28, 32, 48, 72, 96, 120, 144 and 168 hours post-dose
Apparent Volume of Distribution (Vz/f) of Gliclazide
Vz/f was defined as apparent volume of distribution during terminal phase after non-intravenous administration.
Time frame: Pre-dose, 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 16, 24, 28, 32, 48, 72, 96, 120, 144 and 168 hours post-dose
Elimination Half Life (t1/2) of Metformin
Elimination Half Life (t1/2) was defined as the time required for the concentration or amount of drug in the body to be reduced by one-half.
Time frame: Pre-dose, 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 16, 24, 28, 32, 48, 72, 96, 120, 144 and 168 hours post-dose
Elimination Half Life (t1/2) of Gliclazide
Elimination Half Life (t1/2) was defined as the time required for the concentration or amount of drug in the body to be reduced by one-half.
Time frame: Pre-dose, 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 16, 24, 28, 32, 48, 72, 96, 120, 144 and 168 hours post-dose
Apparent Total Body Clearance (CL/f) of Metformin
CL/f was defined as apparent total clearance of the drug from plasma after oral administration.
Time frame: Pre-dose, 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 16, 24, 28, 32, 48, 72, 96, 120, 144 and 168 hours post-dose
Apparent Total Body Clearance (CL/f) of Gliclazide
CL/f was defined as apparent total clearance of the drug from plasma after oral administration.
Time frame: Pre-dose, 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 16, 24, 28, 32, 48, 72, 96, 120, 144 and 168 hours post-dose
Median Residence Time (MRT) for Metformin
MRT is the average time that the molecules introduced into the body stays in the body.
Time frame: Pre-dose, 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 16, 24, 28, 32, 48, 72, 96, 120, 144 and 168 hours post-dose
Median Residence Time (MRT) for Gliclazide
MRT is the average time that the molecules introduced into the body stays in the body.
Time frame: Pre-dose, 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 16, 24, 28, 32, 48, 72, 96, 120, 144 and 168 hours post-dose
Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)
An Adverse event (AE) was defined as any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of study drug, whether or not considered related to the study drug or worsening of pre-existing medical condition, whether or not related to study drug. A serious adverse event (SAE) was an AE that resulted in any of the following outcomes: death; life threatening; persistent/significant disability/incapacity; initial or prolonged inpatient hospitalization; congenital anomaly/birth defect or was otherwise considered medically important. Treatment-emergent are events between first dose of study drug that were absent before treatment or that worsened relative to pre-treatment state. TEAEs included both Serious TEAEs and non-serious TEAEs.
Time frame: Baseline up to Day 72
| Milestone | Treatment Sequence 1 | Treatment Sequence 2 | Treatment Sequence 3 | Treatment Sequence 4 |
|---|---|---|---|---|
| Started | 10 | 10 | 10 | 10 |
| Completed | 10 | 10 | 10 | 10 |
| Not completed | 0 | 0 | 0 | 0 |
| Milestone | Treatment Sequence 1 | Treatment Sequence 2 | Treatment Sequence 3 | Treatment Sequence 4 |
|---|---|---|---|---|
| Started | 10 | 10 | 10 | 10 |
| Completed | 10 | 9 | 10 | 10 |
| Not completed | 0 | 1 | 0 | 0 |
| Withdrew: Withdrawal by subject | 0 | 1 | 0 | 0 |
| Milestone | Treatment Sequence 1 | Treatment Sequence 2 | Treatment Sequence 3 | Treatment Sequence 4 |
|---|---|---|---|---|
| Started | 10 | 9 | 10 | 10 |
| Completed | 9 | 9 | 8 | 9 |
| Not completed | 1 | 0 | 2 | 1 |
| Withdrew: Withdrawal by subject | 1 | 0 | 2 | 1 |
| Milestone | Treatment Sequence 1 | Treatment Sequence 2 | Treatment Sequence 3 | Treatment Sequence 4 |
|---|---|---|---|---|
| Started | 9 | 9 | 8 | 9 |
| Completed | 9 | 9 | 8 | 9 |
| Not completed | 0 | 0 | 0 | 0 |
| nanogram*hour per milliliter (ng*h/ml) | Metformin-Gliclazide Combination | Metformin and Gliclazide Separately | Metformin |
|---|---|---|---|
| Area Under the Plasma Concentration-Time Curve From Time Zero to Last Measurable Concentration (AUC0-t) of Metformin | 5033.8718 ± 1475.3418 | 6142.2821 ± 1848.4857 | 6090.7932 ± 1543.6463 |
| ng.h/ml | Metformin-Gliclazide Combination | Metformin and Gliclazide Separately | Gliclazide |
|---|---|---|---|
| Area Under the Plasma Concentration-Time Curve From Time Zero to Last Measurable Concentration (AUC0-t) of Gliclazide | 20707.7394 ± 8267.0653 | 20280.3103 ± 8219.1520 | 21205.2514 ± 7638.0877 |
| nanogram per milliliter (ng/ml) | Metformin-Gliclazide Combination | Metformin and Gliclazide Separately | Metformin |
|---|---|---|---|
| Maximum Observed Plasma Concentration (Cmax) of Metformin | 806.3895 ± 279.5063 | 1011.3941 ± 309.8136 | 977.2693 ± 262.4312 |
| ng/ml | Metformin-Gliclazide Combination | Metformin and Gliclazide Separately | Gliclazide |
|---|---|---|---|
| Maximum Observed Plasma Concentration (Cmax) of Gliclazide | 972.168 ± 312.7305 | 892.6201 ± 259.7459 | 836.7239 ± 251.6451 |
AUC (0-inf) is defined as the area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time (0-inf).
| ng*h/ml | Metformin-Gliclazide Combination | Metformin and Gliclazide Separately | Metformin |
|---|---|---|---|
| Area Under the Plasma Concentration-time Curve From Time Zero to Infinity (AUC0-inf) of Metformin | 5313.3897 ± 1549.2688 | 6388.9849 ± 1857.6205 | 6341.5658 ± 1560.7170 |
AUC (0-inf) is defined as the area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time (0-inf).
| ng*h/ml | Metformin-Gliclazide Combination | Metformin and Gliclazide Separately | Gliclazide |
|---|---|---|---|
| Area Under the Plasma Concentration-time Curve From Time Zero to Infinity (AUC0-inf) of Gliclazide | 21495.2343 ± 8358.3373 | 21120.6761 ± 8270.5092 | 22136.9988 ± 7687.4829 |
Vz/f was defined as apparent volume of distribution during terminal phase after non-intravenous administration.
| Milliliter | Metformin-Gliclazide Combination | Metformin and Gliclazide Separately | Metformin |
|---|---|---|---|
| Apparent Volume of Distribution (Vz/f) of Metformin | 1893618.4672 ± 1346880.1198 | 1414424.1926 ± 643556.2088 | 1489164.0229 ± 818767.0681 |
Vz/f was defined as apparent volume of distribution during terminal phase after non-intravenous administration.
| Milliliter | Metformin-Gliclazide Combination | Metformin and Gliclazide Separately | Gliclazide |
|---|---|---|---|
| Apparent Volume of Distribution (Vz/f) of Gliclazide | 31636.8920 ± 7584.1651 | 32601.0115 ± 7057.8050 | 31413.9679 ± 6422.4920 |
Elimination Half Life (t1/2) was defined as the time required for the concentration or amount of drug in the body to be reduced by one-half.
| Hours | Metformin-Gliclazide Combination | Metformin and Gliclazide Separately | Metformin |
|---|---|---|---|
| Elimination Half Life (t1/2) of Metformin | 6.7151 ± 5.1372 | 5.9796 ± 2.8442 | 6.3048 ± 3.7114 |
Elimination Half Life (t1/2) was defined as the time required for the concentration or amount of drug in the body to be reduced by one-half.
| Hours | Metformin-Gliclazide Combination | Metformin and Gliclazide Separately | Gliclazide |
|---|---|---|---|
| Elimination Half Life (t1/2) of Gliclazide | 15.3086 ± 6.0231 | 15.4587 ± 5.6007 | 15.6222 ± 5.2904 |
CL/f was defined as apparent total clearance of the drug from plasma after oral administration.
| Milliliter per Hour (mL/ h) | Metformin-Gliclazide Combination | Metformin and Gliclazide Separately | Metformin |
|---|---|---|---|
| Apparent Total Body Clearance (CL/f) of Metformin | 207132.8293 ± 70959.4296 | 170273.4024 ± 51108.0288 | 167260.5841 ± 39170.7306 |
CL/f was defined as apparent total clearance of the drug from plasma after oral administration.
| mL/h | Metformin-Gliclazide Combination | Metformin and Gliclazide Separately | Gliclazide |
|---|---|---|---|
| Apparent Total Body Clearance (CL/f) of Gliclazide | 1572.5246 ± 516.3724 | 1606.8952 ± 569.4811 | 1498.9932 ± 463.2158 |
MRT is the average time that the molecules introduced into the body stays in the body.
| Hours | Metformin-Gliclazide Combination | Metformin and Gliclazide Separately | Metformin |
|---|---|---|---|
| Median Residence Time (MRT) for Metformin | 8.3952 ± 3.0758 | 7.5836 ± 1.6807 | 7.7636 ± 2.0658 |
MRT is the average time that the molecules introduced into the body stays in the body.
| Hours | Metformin-Gliclazide Combination | Metformin and Gliclazide Separately | Gliclazide |
|---|---|---|---|
| Median Residence Time (MRT) for Gliclazide | 23.0593 ± 7.8010 | 24.4927 ± 7.7484 | 25.8590 ± 7.5834 |
An Adverse event (AE) was defined as any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of study drug, whether or not considered related to the study drug or worsening of pre-existing medical condition, whether or not related to study drug. A serious adverse event (SAE) was an AE that resulted in any of the following outcomes: death; life threatening; persistent/significant disability/incapacity; initial or prolonged inpatient hospitalization; congenital anomaly/birth defect or was otherwise considered medically important. Treatment-emergent are events between first dose of study drug that were absent before treatment or that worsened relative to pre-treatment state. TEAEs included both Serious TEAEs and non-serious TEAEs.
| Participants | Metformin-Gliclazide Combination | Metformin and Gliclazide Separately | Metformin | Gliclazide |
|---|---|---|---|---|
| TEAEs | 9 | 6 | 7 | 8 |
| SAEs | 0 | 0 | 0 | 0 |
Collected over Baseline up to Day 72. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Metformin-Gliclazide Combination | 0/35 (0%) | 0/35 (0%) | 9/35 (25.7%) |
| Metformin and Gliclazide Separately | 0/35 (0%) | 0/35 (0%) | 6/35 (17.1%) |
| Metformin | 0/35 (0%) | 0/35 (0%) | 7/35 (20%) |
| Gliclazide | 0/35 (0%) | 0/35 (0%) | 8/35 (22.9%) |
| Event | Metformin-Gliclazide Combination | Metformin and Gliclazide Separately | Metformin | Gliclazide |
|---|---|---|---|---|
| AnemiaBlood and lymphatic system disorders | 5/35 | 2/35 | 5/35 | 7/35 |
| Elevated aspartate aminotrasferaseInvestigations | 1/35 | 0/35 | 5/35 | 1/35 |
| Elevated alanine aminostrasferaseInvestigations | 1/35 | 0/35 | 4/35 | 1/35 |
| Elevated triglyceridesInvestigations | 1/35 | 3/35 | 2/35 | 0/35 |
| UrethritisInfections and infestations | 1/35 | 2/35 | 0/35 | 0/35 |
| High cholesterolInvestigations | 0/35 | 0/35 | 1/35 | 0/35 |
| Vasovagal reactionNervous system disorders | 0/35 | 1/35 | 0/35 | 0/35 |
| HeadacheNervous system disorders | 1/35 | 0/35 | 0/35 | 1/35 |
| DizzinessNervous system disorders | 0/35 | 0/35 | 0/35 | 1/35 |
| OdynophagiaGastrointestinal disorders | 0/35 | 1/35 | 0/35 | 1/35 |
All participants who were randomized into the study.
| Age, Continuous(Years) | Treatment Sequence 1 | Treatment Sequence 2 | Treatment Sequence 3 | Treatment Sequence 4 | Total |
|---|---|---|---|---|---|
| Mean | 22.8 ± 9.8 | 23.9 ± 3.7 | 31.5 ± 8.3 | 25.7 ± 5.2 | 27.3 ± 7.5 |
| Sex: Female, Male(Participants) | Treatment Sequence 1 | Treatment Sequence 2 | Treatment Sequence 3 | Treatment Sequence 4 | Total |
|---|---|---|---|---|---|
| Female | 6 | 3 | 3 | 5 | 17 |
| Male | 4 | 7 | 7 | 5 | 23 |
| Ethnicity (NIH/OMB)(Participants) | Treatment Sequence 1 | Treatment Sequence 2 | Treatment Sequence 3 | Treatment Sequence 4 | Total |
|---|---|---|---|---|---|
| Hispanic or Latino | 10 | 10 | 10 | 10 | 40 |
| Not Hispanic or Latino | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Feb 2018 to primary completion in Apr 2018, 2 months.
Results were first posted in Jul 2019, 1 year 2 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Metformin · Gliclazide
Merck KGaA, Darmstadt, Germany →